<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2006</study_start_year><condition>carcinoma colo-rettale avanzato</condition><condition>Colorectal neoplasms malignant</condition><disease>Colorectal Neoplasms Malignant</disease><disease>Carcinoma Colo-rettale Avanzato</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2520633</full_dataset_link><location>Italy</location><study_start_month>11</study_start_month><keyword>ERBITUX*INFUS 1FL 50ML 2MG/ML</keyword><keyword>MITOMYCIN C*INIET 1FL 10MG</keyword><keyword>CAMPTO*1FL 100MG/5ML</keyword><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>Cetuximab + Irinotecano vs chemoterapia standard nel carcinoma colo-rettale avanzato pretrattato non resecabile esprimente EGFR</name><description>Primary objectives: Sopravvivenza globale</description><dates><creation>2006-11-15</creation></dates><accession>2520633</accession><cross_references><EU Clinical Trials Register>2006-004849-42</EU Clinical Trials Register></cross_references></HashMap>